CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer imm | CIP, Cancer Immunology Project
CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy
New Paper by USERN Interest Groups
Adoptive T-cell therapy (ACT) is one of the most distinctive modalities of this therapeutic approach, which seeks to harness the potential of combating cancer cells by using autologous or allogenic tumor-specific T-cells.
Here, we aim to review and categorize the recent breakthroughs of genetically modified TCR/CAR T-cells through CRISPR/Cas9 technology and address the pearls and pitfalls of each method.
